186 related articles for article (PubMed ID: 27287210)
1. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.
Lacouture ME; Keefe DM; Sonis S; Jatoi A; Gernhardt D; Wang T; Doherty JP; Giri N; Nadanaciva S; O'Connell J; Sbar E; Piperdi B; Garon EB
Ann Oncol; 2016 Sep; 27(9):1712-8. PubMed ID: 27287210
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
3. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Kim DW; Garon EB; Jatoi A; Keefe DM; Lacouture ME; Sonis S; Gernhardt D; Wang T; Giri N; Doherty JP; Nadanaciva S; O'Connell J; Sbar E; Cho BC
Lung Cancer; 2017 Apr; 106():76-82. PubMed ID: 28285698
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
[TBL] [Abstract][Full Text] [Related]
5. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ
J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
[TBL] [Abstract][Full Text] [Related]
7. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Ramalingam SS; Jänne PA; Mok T; O'Byrne K; Boyer MJ; Von Pawel J; Pluzanski A; Shtivelband M; Docampo LI; Bennouna J; Zhang H; Liang JQ; Doherty JP; Taylor I; Mather CB; Goldberg Z; O'Connell J; Paz-Ares L
Lancet Oncol; 2014 Nov; 15(12):1369-78. PubMed ID: 25439691
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Park K; Cho BC; Kim DW; Ahn MJ; Lee SY; Gernhardt D; Taylor I; Campbell AK; Zhang H; Giri N; Letrent SP; O'Connell J; Heo DS
J Thorac Oncol; 2014 Oct; 9(10):1523-31. PubMed ID: 25521398
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Zhang B; Shi C; Gao Z; Zhong H; Xiong L; Gu A; Wang W; Chu T; Zhang W; Wang H; Zhang X; Zhong R; Han B
BMC Cancer; 2022 Mar; 22(1):294. PubMed ID: 35305596
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study).
Iwasaku M; Uchino J; Yamada T; Chihara Y; Shimamoto T; Tamiya N; Kaneko Y; Kiyomi F; Takayama K
Transl Lung Cancer Res; 2019 Aug; 8(4):519-523. PubMed ID: 31555524
[TBL] [Abstract][Full Text] [Related]
12. Effects of dose modifications on the safety and efficacy of dacomitinib for
Corral J; Mok TS; Nakagawa K; Rosell R; Lee KH; Migliorino MR; Pluzanski A; Linke R; Devgan G; Tan W; Quinn S; Wang T; Wu YL
Future Oncol; 2019 Aug; 15(24):2795-2805. PubMed ID: 31313942
[No Abstract] [Full Text] [Related]
13. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
14. Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.
Mok T; Lee K; Tang M; Leung L
Future Oncol; 2014 Apr; 10(5):813-22. PubMed ID: 24799062
[TBL] [Abstract][Full Text] [Related]
15. The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Paty J; Sandin R; Reisman A; Wu YL; Migliorino MR; Zhou X; Cheng Y; Lee KH; Nakagawa K; Niho S; Corral J; Płużański A; Linke R; Meyers O; Mok TS
Future Oncol; 2021 Mar; 17(7):783-794. PubMed ID: 33164569
[No Abstract] [Full Text] [Related]
16. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
Jänne PA; Ou SI; Kim DW; Oxnard GR; Martins R; Kris MG; Dunphy F; Nishio M; O'Connell J; Paweletz C; Taylor I; Zhang H; Goldberg Z; Mok T
Lancet Oncol; 2014 Dec; 15(13):1433-1441. PubMed ID: 25456362
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.
Abdul Razak AR; Soulières D; Laurie SA; Hotte SJ; Singh S; Winquist E; Chia S; Le Tourneau C; Nguyen-Tan PF; Chen EX; Chan KK; Wang T; Giri N; Mormont C; Quinn S; Siu LL
Ann Oncol; 2013 Mar; 24(3):761-9. PubMed ID: 23108949
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors.
Calvo E; Soria JC; Ma WW; Wang T; Bahleda R; Tolcher AW; Gernhardt D; O'Connell J; Millham R; Giri N; Wick MJ; Adjei AA; Hidalgo M
Clin Cancer Res; 2017 Mar; 23(5):1177-1185. PubMed ID: 27733479
[No Abstract] [Full Text] [Related]
19. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel RMJM; van Brummelen EMJ; Eskens FALM; Huijberts SCFA; de Vos FYFL; Lolkema MPJK; Devriese LA; Opdam FL; Marchetti S; Steeghs N; Monkhorst K; Thijssen B; Rosing H; Huitema ADR; Beijnen JH; Bernards R; Schellens JHM
Br J Cancer; 2020 Apr; 122(8):1166-1174. PubMed ID: 32147669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]